Evidence map›Paper›PMID 37042989›Full record

ArticleChirurgie (Heidelberg, Germany)2023

[Diagnostics, treatment and aftercare of anal cancer].

Felix Aigner, Robert Siegel

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Chirurgie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Felix AignerChirurgische Abteilung, Krankenhaus der Barmherzigen Brüder Graz, Graz, Österreich. felix.aigner@bbgraz.at.
Robert SiegelKlinik für Allgemein‑, Viszeral- und Onkologische Chirurgie, Helios Klinikum Berlin-Buch, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin · DEHelios Hospital Berlin-Buch · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the increasing incidence, anal cancer is still a rare gastrointestinal tumor, so that due to the broadness of the primary care there is often little experience in the care of affected patients. Squamous cell cancer (SCC) constitutes more than 90% of all anal cancers and is nearly always associated with an infection by the human papillomavirus. This article concentrates on SCC of the anal canal and anal margin. The focus is on the primary diagnostics, surgical treatment, response assessment and aftercare. Treatment is carried out according to the decision of the interdisciplinary tumor board, independent of the tumor location and stage. Anal margin cancer in stage I (and IIa) can be successfully treated by an R0 excision. Combined chemoradiotherapy as the standard treatment in stages II and III is briefly summarized. The article is essentially based on the new German S3 guidelines on anal cancer.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellAftercareChemoradiotherapyCombined Modality TherapyHumansNeoplasm StagingAbdomino-perineal resectionAnal canalAnal marginChemoradiotherapySquamous cell carcinoma

Identifiers

PMID37042989
OpenAlexW4365135094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.